Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study

Diseases of the Colon and Rectum

Volumn 53, Issue 10, 2010, Pages 1432-1438

  Ahmed, Shahid ^a   Ahmad, Imran ^a   Zhu, Tong ^a   Arnold, Florence P ^a   Faiz Anan, Ghadeer ^b   Sami, Amer ^a   Yadav, Sunil K ^a   Alvi, Riaz ^a   Haider, Kamal ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adjuvant chemotherapy; Adjuvant therapy; Colorectal cancer; Completion of adjuvant treatment; Prognostic factors; Timing of adjuvant therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; COLON TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; RECTUM TUMOR; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 78049367576     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181e78815     Document Type: Article

References (23)

1. O'Connell MJ, Mailliard J, Kahn MJ, et al. Controlled trial of flurouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246-250.
2. Andre T, Boni, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III COLON CANCER in the MOSAIC Trial. J Clin Oncol. 2009;27:3109-3116.
3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
4. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507.
5. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005;16:549-557.
6. Andre T, Colin P, Louvet, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21:2896-2903.
7. Glimelius B, Cedermark B, Dahl O, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol. 2005;44:904-912.
8. Taal BG, Van Tinteren H, Zoetmulder FA; NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 2001;85:1437-1443.
9. Hershman D, Hall MJ, Wang X. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107:2581-2588.
10. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24:2368-2375.
11. Dobie SA, Baldwin LM, Dominitz JA, et al. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006;98:610-661.
12. Morris M, Platell C, Fritschi L, et al. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96:701-707.
13. Bayraktar UD, Bayraktar S, Herna S. Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer [abstract]? J Clin Oncol. 2009;27:4046.
14. Carlsson G, Albertsson P, Gustavsson B. Delayed start of adjuvant 5-FU/leucovorin based chemotherapy in colon cancer is safe up to 12 weeks postoperatively. J Clin Oncol. 2007;25:4056.
15. zaykowski P, Gill S, Kennecke H, et al. Adjuvant chemotherapy (AC) for stage 3 colon cancer: does timing matter [abstract]? Paper presented at the American Society for Clinical Oncology Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL.
16. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979-994.
17. Chang GJ, Rodriguez-Bigas MA, Skibber JM. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99:433-441.
18. Griffin MR, Bergstralh EJ, Coffey RJ, et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer. 1987;60:2318-2324.
19. Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer. 1996;32A:295-302.
20. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer. 1998;34:2176-2183.
21. Kapiteijn E, Liefers GJ, Los LC, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001;195:171-178.
22. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294:2703-2711.
23. Ratto C, Sofo L, Ippoliti M, et al. Prognostic factors in colorectal cancer: literature review for clinical application. Dis Colon Rectum. 1998;4:1033-1049.